Skip to main content
Premium Trial:

Request an Annual Quote

Ingalls: New growth for NuTec


Harold Ingalls admits it’s somewhat difficult to act as CEO of a bioinformatics company with a primarily financial background. But that’s just what he’s doing at NuTec Sciences.

Founder and former CEO Michael Keehan is handing the title to Ingalls, 54, because of his 30-some years of financial and operating experience. Keehan anticipates it’s this type of CEO NuTec needs for fast growth.

Indeed, Ingalls is looking forward to growing the company, speculating that NuTec may one day expand from supplying software and computing services. “I see us actually using some of our tools on impacting the drug discovery process, and really participating ourselves,” he says.

Before that happens, Ingalls says the company will work on its business model, hire new people, and look to VC and private equity sources for new funding. In addition, NuTec is building the final stages of its new IBM supercomputer, slated to be the fastest non-governmental system.

Ingalls entered the business arena at Andersen Consulting. From there, he began a stint at Waste Management by building a camp for workers and vehicles in Saudi Arabia in the early 1980s. He later joined chemical manufacturing and distribution company LaRoche in July of 1996, and became CEO less than two years later.

Despite all his moves, Chicago-born Ingalls has always pursued his love of golf. Within reason, that is. “Fortunately for me and my family, I don’t rely on golf as a source of income,” he admits.

— Alison McCook


The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.